Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

Insomnia Clinical Trial

Official title:

A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00857220
• Other study ID #: 190-247
• Status: Completed
• Phase: Phase 3
• First received: March 4, 2009
• Last updated: September 25, 2017
• Start date: May 2009
• Est. completion date: October 2011

Study information

• Verified date: September 2017
• Source: Sunovion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.

Description:

This is a multi center, open label, long term safety study in pediatric subjects 6 through 17 years of age, inclusive, with a diagnosis of ADHD associated insomnia. Subjects who complete Study 190 246 (Rollover subjects) and meet the study enrollment criteria will be allowed to participate in this long term safety study. Additionally, Treatment naïve subjects will be enrolled in this long term safety study in order to meet the overall subject enrollment objective of obtaining 100 subjects with 12 months of treatment. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 304
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

Inclusion Criteria:

• Subject is male or female 6 17 years of age, inclusive, at the time of consent.

• Subject must have a diagnosis of ADHD as defined by DSM-IV criteria • The diagnosis for Rollover subjects will be taken from the Screening visit of Study 190 246. Treatment naïve subjects will have these assessments performed at the Screening visit.

• Subject must have documented ADHD associated insomnia, defined as the subject or subject's parent/legal guardian having reported repeated difficulty with sleep initiation (sleep latency >30 minutes) or consolidation (wake time after sleep onset > 45 minutes),>despite adequate age appropriate time and opportunity for sleep.

• Subject has either >30 minutes latency to persistent sleep (LPS) or >45 minutes wake time after sleep onset (WASO) demonstrated by PSG.

• Subject or subject's parent/legal guardian should have reported daytime functional impairment as a result of sleep problems.

• Subject or subject's parent/legal guardian should have reported attempted and failed behavioral interventions for sleep problems, including a regular bedtime and rise time.

• Subject's sleep disturbance must not be attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication whether it is being used as intended or in an illicit manner.

• Female subjects =8 years of age must have a negative serum pregnancy test at screening

• Subject must be in good general health.

• Subject must be able to swallow tablets.

• If subjects are currently taking medication for ADHD, they must be on a stable dose and regimen for at least one month, and preferably for at least 3 months prior to the time of consent

Exclusion Criteria:

• Subject with weight <10th percentile for age and gender

• Subject has any clinically significant or unstable medical abnormality/illness

• Subject has a documented history of Bipolar I or II Disorder, major depression, conduct disorder, generalized anxiety disorder (other than obsessive-compulsive disorder) or any history of psychosis, as determined by medical or psychiatric history or as determined by clinical interview using the MINI-Kid at Visit 1.

• Subject has periodic limb movement >5 times per hour, as demonstrated on PSG.

• Subject has sleep disordered breathing, as demonstrated on PSG.

• Subject has another primary sleep disorder (or secondary sleep disorder that is causing clinical impairment or any other known or suspected medical or psychiatric condition that has affected or may affect sleep

• Subject has a history of circadian rhythm disorder or will travel across =3 time zones more than once during the study.

• Subject has organic brain disease, or a history of febrile seizures.

• Subject is, in the opinion of the investigator, at suicidal or homicidal risk.

• Female subject who is pregnant, lactating or planning to become pregnant.

• Subject is taking any psychotropic or disallowed medications,

• Subject has a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.

• Subject has a history of allergic reaction or has a known or suspected sensitivity to racemic zopiclone, eszopiclone, or any substance that is contained in the formulation.

• Subject has a history of alcohol or substance abuse within 3 months of study participation

• Subject has participated in any investigational study within 30 days prior to study entry or is currently participating in another clinical trial, except Study 190 246.

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention Deficit Hyperactivity Disorder
• Hyperkinesis
• Insomnia
• Sleep Initiation and Maintenance Disorders

Intervention

Drug:
• eszopiclone
One 2 mg tablet per day for 12 months
• eszopiclone
one 3mg tablet per day for 12 months

Locations

Country	Name	City	State
United States	Academy of Clinical Research	Arlington	Texas
United States	Sleep Disorders Center of Georgia	Atlanta	Georgia
United States	NorthCoast Clinical Trials, Inc.	Beachwood	Ohio
United States	Neurobehavioral Medicine Group	Bloomfield Hills	Michigan
United States	Neuro-Behavioral Clnical Research	Canton	Ohio
United States	AV Institute, Inc.	Carson	California
United States	MD	Chevy Chase	Maryland
United States	Delta Waves, Inc.	Colorado Springs	Colorado
United States	Clinical Innovations, Inc.	Costa Mesa	California
United States	Pillar Clinical Research, LLC	Dallas	Texas
United States	InSite Clinical Research	DeSoto	Texas
United States	Mountain West Clinical Trials	Eagle	Idaho
United States	Suburban Lung Associates, SC	Elk Grove Village	Illinois
United States	Cutting Edge Research of Enid	Enid	Oklahoma
United States	Precise Research Centers	Flowood	Mississippi
United States	Sarkis Clinical Trials	Gainesville	Florida
United States	Behavioral Research Specialists, LLC	Glendale	California
United States	Cyn3rgy Research	Gresham	Oregon
United States	MD Clinical	Hallandale Beach	Florida
United States	ActivMed Practices and Research	Haverhill	Massachusetts
United States	Clinical Research Center of Nevada	Henderson	Nevada
United States	Amedica Research Institute, Inc.	Hialeah	Florida
United States	Allegiant Clinical Research	Houston	Texas
United States	Claghorn-Lesem Research Clinic, Ltd.	Houston	Texas
United States	MD	Houston	Texas
United States	Sun Valley Research Center	Imperial	California
United States	Davis Clinic	Indianapolis	Indiana
United States	Goldpoint Clinical Research, LLC	Indianapolis	Indiana
United States	Holston Medical Group	Kingsport	Tennessee
United States	Eastside Therapeutic Resource	Kirkland	Washington
United States	Lake Charles Clinical Trials	Lake Charles	Louisiana
United States	Center for Psychiatry and Behavioral Medicine, Inc.	Las Vegas	Nevada
United States	Behavioral Clinical Research Inc.	Lauderhill	Florida
United States	Behavioral Clinical Research, Inc.	Lauderhill	Florida
United States	Capstone Clinical Research	Libertyville	Illinois
United States	Midwest Children's Health Research Institute	Lincoln	Nebraska
United States	Premier Psychicatric Research Institute, LLC	Lincoln	Nebraska
United States	Clinical Study Centers, LLC	Little Rock	Arkansas
United States	Brownsboro Park Pediatrics	Louisville	Kentucky
United States	Pediatric Neurology and Epilepsy Center	Loxahatchee Groves	Florida
United States	Florida Clinical Research Center, LLC	Maitland	Florida
United States	Cleveland Sleep Research Center	Middleburg Heights	Ohio
United States	North Star Medical Research, LLC	Middleburg Heights	Ohio
United States	AMR Baber Research, Inc.	Naperville	Illinois
United States	Nassim, McMonigle, Mescia & Associates	New Albany	Indiana
United States	Louisiana Research Associates, Inc.	New Orleans	Louisiana
United States	Neurocare, Inc.	Newton	Massachusetts
United States	ActivMed Practices and Research	North Andover	Massachusetts
United States	Scientific Clinical Research Inc.	North Miami	Florida
United States	Excell Research, Inc.	Oceanside	California
United States	North County Clinical Research (NCCR)	Oceanside	California
United States	Cutting Edge Research Group	Oklahoma City	Oklahoma
United States	Eminence Research LLC	Oklahoma City	Oklahoma
United States	IPS Research Company	Oklahoma City	Oklahoma
United States	Pahl Pharmaceutical Professionals, LLC	Oklahoma City	Oklahoma
United States	SP Research	Oklahoma City	Oklahoma
United States	Pacific Clinical Research Medical Group	Orange	California
United States	SDS Clinical Trials, Inc.	Orange	California
United States	Medical Research Group of Central Florida	Orange City	Florida
United States	Aspen Clinical Research, LLC	Orem	Utah
United States	Florida Institute for Clinical Research, LLC	Orlando	Florida
United States	Psychiatric Associates	Overland Park	Kansas
United States	Pedia Research, LLC	Owensboro	Kentucky
United States	CRI Worldwide	Philadelphia	Pennsylvania
United States	DMI Research Inc.	Pinellas Park	Florida
United States	The Mech Center	Plano	Texas
United States	Oregon Center for Clinical Investigations, Inc.	Portland	Oregon
United States	Global Medical Institutes, LLC	Princeton	New Jersey
United States	Alliance Research Group	Richmond	Virginia
United States	Clinical Innovations, Inc.	Riverside	California
United States	Northwest Behavioral Research Center	Roswell	Georgia
United States	Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)	Salem	Oregon
United States	Road Runner Research	San Antonio	Texas
United States	Artemis Institute for Clinical Research	San Diego	California
United States	Clinical Innovations	San Diego	California
United States	Apex Research Institute	Santa Ana	California
United States	Clinical Innovations, Inc.	Santa Ana	California
United States	Neuropsychiatric Research Center of Orange County	Santa Ana	California
United States	Florida Sleep Institute	Spring Hill	Florida
United States	Clinical Nuerophysiology Services, PC	Sterling Heights	Michigan
United States	SomnoMedics, LLC	Tampa	Florida
United States	REM Medical Clinical Research	Tucson	Arizona
United States	Paradigm Research Professonals, LLP	Tulsa	Oklahoma
United States	Tulsa Clinical Research	Tulsa	Oklahoma
United States	Sleep and Behavior Medicine Institute	Vernon Hills	Illinois
United States	Brighton Research Group, LLC	Virginia Beach	Virginia
United States	Omega Medical Research	Warwick	Rhode Island
United States	Elite Clinical Trials, Inc.	Wildomar	California
United States	CRI Worldwide, LLC	Willingboro	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Sunovion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Incidence of Adverse Events		12 Months (from the 1st dose to the end of study)
Secondary	Overall Incidence of Skin Reactions: Number of Events		12 Months (from the 1st dose to the end of study)
Secondary	Overall Incidence of Skin Reactions: Number of Participant Affected		12 Months (from the 1st dose to the end of study)
Secondary	Columbia-Suicide Severity Rating Scale (C-SSRS) Item Responses	The C-SSRS is a physician-completed scale to assess any suicidal ideation and suicidal behavior. The C-SSRS contained questions about suicidal behavior and suicidal ideation. Subjects were placed into categories for suicidal behavior and for suicidal ideation based on their responses to various questions. Any suicidality was defined as suicidal behavior or suicidal ideation. The suicidal behavior categories were determined based on the response to the questions under suicidal behavior (Completed Suicide, Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior).The suicidal ideation categories were determined by examining the response to 5 questions under suicidal ideation (Wish to be Dead, Nonspecific Active Suicidal Thoughts, Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, Active Suicidal Ideation with Some Intent to Act, without Specific Plan, Active Suicidal Ideation with Specific Plan and Intent).	12 Months
Secondary	Change From Baseline in Coding Copy Subtest A or B, or Digit Symbol Substitution Test (DSST)at Month 12	These tests are standardized information processing tasks to assess recognition and recoding of sensory information. The subject was given 90 seconds to complete as many substitutions of symbols as possible according to a code provided on top of the sheet. The Coding Copy Subtest A was used for subjects 6 to 7 years of age, the Coding Copy Subtest B was used for subjects 8 to 16 years of age, and the DSST was used for subjects 17 years of age. The DSST consists of rows containing small blank squares, each paired with a randomly assigned numbers 1-9. Above the rows is a key that pairs each number with a symbol. The subject must fill in the blank spaces with the matching symbol that is in the key. For the Subcopy tests the subject simply copies the symbol above each empty square. Scaled scores are used to account for age differences among test takers. Scaled scores range from 1 to 19, and higher scores indicate higher cognitive function.	Baseline and 12 Months (from the 1st dose to the end of study)
Secondary	Clinical Global Impression (CGI) Improvement Score as Assessed by Parent/Caregiver or Child at Month 12	A 7-point scale was used for improvement with numeric values assigned to each of the responses: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), and very much worse (7).	Baseline and 12 Months (from the 1st dose to the end of study)
Secondary	Change From Baseline at Month 12 in Subjective Sleep Latency (SL)	Sleep latency is the amount of time it takes to fall asleep after the lights have been turned off.	Baseline and 12 Months (from the 1st dose to the end of study)
Secondary	Change From Baseline in Child Behavior Checklist (CBCL)	CBCL was completed by parents or guardians who saw the child in home-like settings. It includes several competence items, open-ended items for describing the child's illnesses, disabilities, concerns about the child, best things about the child, and several items to rate behavioral, emotional, and social problems. Responses are recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The checklist contains 120 questions. The standardized score is computed by determining the z-score by subtracting the mean for the subject's age group and gender from the raw score and then dividing this by the standard deviation for the subject's age group and gender. Next, multiply the zscore by 15 and then add 100. For activities scale, social scale, school scale, and total competence scale, higher values indicate higher competencies. For Internalizing problems, externalizing problems, and total problems, higher values indicate more problems.	Baseline and 12 Months (from the 1st dose to the end of study)
Secondary	Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS)at Month 12	The PDSS total score ranges from a low of 0 where the individual is endorsing each item at the lowest level of daytime sleepiness to a high of 32 where the individual is endorsing each item at the highest level of daytime sleepiness.	Baseline and 12 Months (from the 1st dose to the end of study)
Secondary	Change From Baseline in Conners' Continuous Performance Test II (CCPT II)	The CCPT-II is a computer-based 14-minute, visual-performance task. During an administration, respondents were required to press the space bar or click the mouse whenever any letter except the target letter appears on the screen. The speed at which the letters were presented varied during the administration. There were 6 blocks, with 3 sub-blocks, each containing 20 trials (letter presentations). The interstimulus intervals (ISIs) were 1, 2, and 4 seconds with a display time of 250 milliseconds. The order in which the different ISIs were presented varied between blocks. Conners' CCPT-II provides the following measures:% Omissions,% Commissions, Hit Reaction Time, Hit Reaction Time Standard Error,Variability of Standard Error, Detectability (d'), Response Style (beta), Perseverations, Hit Reaction Time Block Change (Vigilance Measure), Hit Standard Error Block Change (Vigilance Measure), Hit Reaction Time ISI change, and Hit Standard Error ISI Change, Confidence Index.	Baseline and 12 Months (from the 1st dose to the end of study)
Secondary	Change From Baseline at Month 12 in Subjective Wake Time After Sleep Onset (WASO)	The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. WASO was assessed based on the responses to the sleep questionnaire.	Baseline and 12 Months (from the 1st dose to the end of study)
Secondary	Change From Baseline at Month 12 in Subjective Number of Awakening After Sleep Onset (NAASO)	The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. NAASO was assessed based on the responses to the sleep questionnaire.	Baseline and 12 Months (from the 1st dose to the end of study)
Secondary	Change From Baseline at Month 12 in Subjective Total Sleep Time (TST).	The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. TST was assessed based on the responses to the sleep questionnaire.	Baseline and 12 Months (from the 1st dose to the end of study)
Secondary	Change From Baseline in Pediatric Quality of Life Scale	The SF-10™ Health Survey for Children is a 10-item care-giver completed assessment designed to measure children's health-related quality of life. The scale asked questions about the child's physical wellness, feelings, behavior, and activities at school and with family and friends. The SF-10 physical and psychosocial summary measures were scored such that higher scores indicated more favorable functioning. The Physical Summary Score is computed by summing values for questions 1, 2a, 2b, 3 and 5 and standardizing scores by normalizing to a total possible score of 0-100 with higher scores representing more positive indications. The Psychosocial Summary Score is computed by summing questions 4, 6, 7, 8, and 9 and standardizing scores by normalizing to a total possible score of 0-100 with higher scores representing more positive indications.	Baseline and 12 Months (from the 1st dose to the end of study)